In the last years, there is great impetus to discover new biomarkers in RCC in order to address the patients toward an appropriate adjuvant therapy. In this regard, miR501-5p that is differentially expressed in RCC and mTOR which in many tumours correlates with a poor prognosis, could represent possible biomarkers. Therefore, miR501-5p expression and mTOR activity will be studied in normal and RCC tissues as well as in kidney cell lines depleted or enriched in miR501-5p sequences. Cell growth, apoptosis, autophagy and related signaling pathways will be analyzed in kidney cells and tissues expressing different levels of miR501-5p in order to evaluate the role of miR501-5p in RCC. High and low miR501-5p expression levels combined with mTOR activity of different RCC tissues will be matched with the outcome of RCC patients to evaluate their possible prognostic role.
A combination of miR501-5p and mTOR as molecular markers for the prognosis of renal carcinomas
MANGOLINI, Alessandra
2014
Abstract
In the last years, there is great impetus to discover new biomarkers in RCC in order to address the patients toward an appropriate adjuvant therapy. In this regard, miR501-5p that is differentially expressed in RCC and mTOR which in many tumours correlates with a poor prognosis, could represent possible biomarkers. Therefore, miR501-5p expression and mTOR activity will be studied in normal and RCC tissues as well as in kidney cell lines depleted or enriched in miR501-5p sequences. Cell growth, apoptosis, autophagy and related signaling pathways will be analyzed in kidney cells and tissues expressing different levels of miR501-5p in order to evaluate the role of miR501-5p in RCC. High and low miR501-5p expression levels combined with mTOR activity of different RCC tissues will be matched with the outcome of RCC patients to evaluate their possible prognostic role.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
